Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Edaravone Mitsubishi-Tokyo.

R Tabrizchi1

  • 1Memorial University of Newfoundland, Faculty of Medicine, Basic Medical Sciences, Health Sciences Centre, St John's, NF, A1B 3V6, Canada. rtabrizc@morgan.ucs.mun.ca

Current Opinion in Investigational Drugs (London, England : 2000)
|March 16, 2001
PubMed
Summary

Edaravone, a free radical scavenger, is being developed to treat cardiovascular diseases and brain injuries like stroke. This compound targets lipoperoxide, a molecule linked to aging and neurodegeneration.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of β-adrenoceptor-mediated relaxation signals in isolated pulmonary artery of Dahl salt-sensitive hypertensive and normotensive rats.

Autonomic & autacoid pharmacology·2010
Same author

Anomalous response to potassium in vascular smooth muscle cells of human saphenous vein.

Autonomic & autacoid pharmacology·2005
Same author

Relaxant responses to calcium channel antagonists and potassium channel opener in human saphenous vein.

Autonomic & autacoid pharmacology·2005
Same author

Omapatrilat. Bristol-Myers Squibb.

Current opinion in investigational drugs (London, England : 2000)·2002
Same author

Pharmacology of adenosine receptors in the vasculature.

Pharmacology & therapeutics·2001
Same author

The influence of phosphodiesterase inhibitor, rolipram, on hemodynamics in lipopolysaccharide-treated rats.

Japanese journal of pharmacology·2001

Area of Science:

  • Neuroscience
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Mitsubishi-Tokyo is developing edaravone (norphenazone), a free radical scavenger.
  • Edaravone targets the lipoperoxide 15-HPETE, which increases with age and is implicated in neurodegeneration.

Purpose of the Study:

  • To evaluate edaravone for potential treatment of cardiovascular disease.
  • To assess edaravone for cerebrovascular ischemia and cerebral edema treatment.
  • To investigate edaravone's efficacy in acute brain infarction and subarachnoid hemorrhage.

Main Methods:

  • Edaravone (norphenazone) functions as a free radical scavenger.
  • The compound's mechanism involves blocking the action of 15-HPETE.
  • Clinical trials, including Phase III for subarachnoid hemorrhage, were conducted.

Main Results:

  • Edaravone has been filed in Japan for acute brain infarction treatment.
  • Phase III trials were underway for subarachnoid hemorrhage.
  • The compound's ability to scavenge free radicals and block 15-HPETE suggests therapeutic potential.

Conclusions:

  • Edaravone shows promise for treating conditions involving oxidative stress and ischemia.
  • Further development is aimed at cardiovascular and cerebrovascular applications.
  • The drug's mechanism may mitigate age-related neurodegeneration.

Related Experiment Videos